European Neuropsychopharmacology
Volume 20, Issue 4 , Pages 245-252 , April 2010

Endogenous cannabinoids in post-mortem brains of Cloninger type 1 and 2 alcoholics

  • Marko Lehtonen

      Affiliations

    • Department of Pharmaceutical Chemistry, University of Kuopio, P.O. Box 1627, FI-70211 Kuopio, Finland
    • Biocenter Kuopio, University of Kuopio, P.O. Box 1627, FI-70211 Kuopio, Finland
    • ,
  • Markus Storvik

      Affiliations

    • Department of Pharmacology and Toxicology, University of Kuopio, P.O. Box 1627, FI-70211 Kuopio, Finland
    • Department of Biosciences, University of Kuopio, P.O. Box 1627, FI-70211, Kuopio, Finland
    • ,
  • Erkki Tupala

      Affiliations

    • Department of Forensic Psychiatry, Niuvanniemi Hospital, University of Kuopio, FI-70240 Kuopio, Finland
    • Deceased.
    • ,
  • Petri Hyytiä

      Affiliations

    • National Institute for Health and Welfare, Department of Alcohol, Drugs and Addiction, P.O. Box 30, FI-00271, Helsinki, Finland
    • ,
  • Jari Tiihonen

      Affiliations

    • Department of Forensic Psychiatry, Niuvanniemi Hospital, University of Kuopio, FI-70240 Kuopio, Finland
    • Corresponding Author InformationCorresponding author. Department of Forensic Psychiatry, Niuvanniemi Hospital, FI-70240 Kuopio, Finland. Tel.: +358 17203202; fax: +358 17203494.
    • ,
  • J.C. Callaway

      Affiliations

    • Department of Neurobiology, A.I. Virtanen Institute for Molecular Sciences, P.O. Box 1627, FI-70211, University of Kuopio, Kuopio, Finland
    • Biocenter Kuopio, University of Kuopio, P.O. Box 1627, FI-70211 Kuopio, Finland

Received 6 October 2009 ,Revised 21 December 2009 ,Accepted 24 December 2009.

References 

  1. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 4rd ed.. Washington, DC: American Psychiatric Press; 1994;
  2. Basavarajappa BS. The endocannabinoid signaling system: a potential target for next-generation therapeutics for alcoholism. Mini Rev. Med. Chem. 2007;7(8):769–779
  3. Bisogno T. Endogenous cannabinoids: structure and metabolism. J. Neuroendocrinol. 2008;20:1–19
  4. Cippitelli A, Bilbao A, Hansson AC, del Arco I, Sommer W, Heilig M, et al. Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats. Eur. J. NeuroSci. 2005;21:2243–2251
  5. Cloninger CR. The psychobiological regulation of social co-operation. Nat. Med. 1995;1:623–624
  6. Colombo G, Serra S, Brunetti G, Gomez R, Melis S, Vacca G, et al. Stimulation of voluntary ethanol intake by cannabinoid receptor agonists in ethanol-preferring sP rats. Psychopharmacology (Berlin). 2002;159:181–187
  7. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce. Nat. Rev. 2008;7:438–455
  8. Di Marzo V, Maccarrone M. FAAH and anandamide: is 2-AG really the odd one out?. Trends Pharmacol. Sci. 2008;29:229–233
  9. Dinh TP, Freund TF, Piomelli D. A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem. Phys. Lipids. 2002;121:149–158
  10. Ferrer B, Bermúdez-Silva FJ, Bilbao A, Alvarez-Jaimes L, Sanchez-Vera I, Giuffrida A, et al. Regulation of brain anandamide by acute administration of ethanol. Biochem. J. 2007;404:97–104
  11. Fowler CJ. The pharmacology of the cannabinoid system — a question of efficacy and selectivity. Mol. Neurobiol. 2007;36:15–25
  12. González S, Cascio MG, Fernandez-Ruiz J, Fezza F, Di Marzo V, Ramos JA. Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res. 2002;954:73–81
  13. González S, Valenti M, de Miguel R, Fezza F, Fernández-Ruiz J, Di Marzo V, et al. Changes in endocannabinoid contents in reward-related brain regions of alcohol-exposed rats and their possible relevance to alcohol relapse. Br. J. Pharmacol. 2004;143:455–464
  14. Hallikainen T, Saito T, Lachman HM, Volavka J, Pohjalainen T, Ryynänen OP, et al. Association between low activity serotonin transporter promoter genotype and early onset alcoholism with habitual impulsive violent behavior. Mol. Psychiatry. 1999;4:385–388
  15. Hansson AC, Bermúdez-Silva FJ, Malinen H, Hyytiä P, Sanchez-Vera I, Rimondini R, et al. Genetic impairment of frontocortical endocannabinoid degradation and high alcohol preference. Neuropsychopharmacology. 2007;32:117–126
  16. Hungund BL, Szakall I, Adam A, Basavarajappa BS, Vadasz C. Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens. J. Neurochem. 2003;84:698–704
  17. Hungund BL, Vinod KY, Kassir SA, Basavarajappa BS, Yalamanchili R, Cooper TB, et al. Upregulation of CB1 receptors and agonist-stimulated [35S]GTPgammaS binding in the prefrontal cortex of depressed suicide victims. Mol. Psychiatry. 2004;9(2):184–190
  18. Hyman SE, Malenka RC. Addiction and the brain: the neurobiology of compulsion and its persistence. Nat. Rev. 2001;2:695–703
  19. Jung KM, Mangieri R, Stapleton C, Kim J, Fegley D, Wallace M, et al. Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. Mol. Pharmacol. 2005;68:1196–1202
  20. Lehtonen M, Reisner K, Auriola S, Wong G, Callaway JC. Mass spectrometric identification of anandamide and 2-arachidonoyl glycerol in nematodes. Chem. Biodivers. 2008;5:2431–2441
  21. Maldonado R, Valverde O, Berrendero F. Involvement of the endocannabinoid system in drug addiction. TRENDS Neurosci. 2006;29:225–232
  22. Mann JJ, Waternaux C, Haas GL, Malone KM. Toward a clinical model of suicidal behavior in psychiatric patients. Am. J. Psychiatry. 1999;156(2):181–189
  23. Mantere T, Tupala E, Hall H, Särkioja T, Räsänen P, Bergström K, et al. Serotonin transporter distribution and density in the cerebral cortex of alcoholic and nonalcoholic comparison subjects: a whole-hemisphere autoradiography study. Am. J. Psychiatry. 2002;159(4):599–606
  24. Palkovits M, Harvey-White J, Liu J, Kovacs ZS, Bobest M, Lovas G, et al. Regional distribution and effects of postmortal delay on endocannabinoid content of the human brain. Neuroscience. 2008;152:1032–1039
  25. Patel S, Rademacher DJ, Hillard CJ. Differential regulation of the endocannabinoids anandamide and 2-arachidonylglycerol within the limbic forebrain by dopamine receptor activity. J. Pharmacol. Exp. Ther. 2003;306:880–888
  26. Patel S, Carrier EJ, Ho W-SV, Rademacher DJ, Cunningham S, Reddy DS, et al. The postmortal accumulation of brain N-arachidonylethanolamine (anandamide) is dependent upon fatty acid amide hydrolase activity. J. Lipid Res. 2005;46:342–349
  27. Repo-Tiihonen E, Virkkunen M, Tiihonen J. Mortality of antisocial male criminals. J. Forensic Psychiatry. 2001;12:677–683
  28. Robbe D, Kopf M, Remaury A, Bockaert J, Manzoni OJ. Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc. Natl. Acad. Sci. U. S. A. 2002;99:8384–8388
  29. Rubio M, McHugh D, Fernández-Ruiz J, Bradshaw H, Walker JM. Short-term exposure to alcohol in rats affects brain levels of anandamide, other N-acylethanolamines and 2-arachidonoyl-glycerol. Neurosci. Lett. 2007;421:270–274
  30. Soyka M, Koller G, Schmidt P, Lesch O-M, Leweke M, Fehr C, et al. Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence, results from a placebo-controlled, double-blind trial. J. Clin. Psychopharmacol. 2008;28:317–324
  31. Storvik M, Tiihonen J, Haukijärvi T, Tupala E. Nucleus accumbens serotonin transporters in alcoholics measured by whole-hemisphere autoradiography. Alcohol. 2006;40:177–184
  32. Thanos PK, Dimitrakakis ES, Rice O, Gifford A, Volkow ND. Ethanol self-administration and ethanol conditioned place preference are reduced in mice lacking cannabinoid CB1 receptors. Behav. Brain Res. 2005;164:206–213
  33. Tiihonen J, Eronen M, Hakola P. Criminality associated with mental disorder and intellectual deficiency. Arch. Gen. Psychiatry. 1993;50:916–918
  34. Tiihonen J, Kuikka J, Bergström K, Hakola P, Karhu J, Ryynänen OP, et al. Altered striatal dopamine re-uptake site densities in habitually violent and non-violent alcoholics. Nat. Med. 1995;1(7):654–657
  35. Tupala E, Tiihonen J. Dopamine and alcoholism: neurobiological basis of ethanol abuse. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2004;28(8):1221–1247
  36. Tupala E, Tiihonen J. Striatal dopamine D1 receptors in type 1 and 2 alcoholics measured with human whole hemisphere autoradiography. Brain Res. 2005;1031(1):20–29
  37. Tupala E, Hall H, Särkioja T, Räsänen P, Tiihonen J. Dopamine-transporter density in nucleus accumbens of type-1 alcoholics. Lancet. 2000;355:380
  38. Tupala E, Hall H, Bergström K, Särkioja T, Räsänen P, Mantere T, et al. Dopamine D(2)/D(3)-receptor and transporter densities in nucleus accumbens and amygdala of type 1 and 2 alcoholics. Mol. Psychiatry. 2001;6(3):261–267
  39. Tupala E, Häkkinen M, Storvik M, Tiihonen J. Striatal dopaminergic terminals in type 1 and type 2 alcoholics measured with [3H]dihydrotetrabenazine and human whole hemisphere autoradiography. Psychiatry Res. 2008;163(1):70–75
  40. Vinod KY, Hungund BL. Endocannabinoid lipids and mediated system: implications for alcoholism and neuropsychiatric disorders. Life Sci. 2005;77(14):1569–1583
  41. Vinod KY, Arango V, Xie S, Kassir SA, Mann JJ, Cooper TB, et al. Elevated levels of endocannabinoids and CB1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims. Biol. Psychiatry. 2005;57:480–486
  42. Vinod KY, Sanguino E, Yalamanchili R, Manzanares J, Hungund BL. Manipulation of fatty acid amide hydrolase functional activity alters sensitivity and dependency to ethanol. J. Neurochem. 2008;104:233–243
  43. Wilson RI, Nicoll RA. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature. 2001;410(6828):588–592

PII: S0924-977X(10)00004-0

doi: 10.1016/j.euroneuro.2009.12.008

European Neuropsychopharmacology
Volume 20, Issue 4 , Pages 245-252 , April 2010

Article Tools

* Image Usage & Resolution